Affinity Asset Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Affinity Asset Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-190,000	Closed	-$12.9M	–	89
2022 Q3	$12.9M	Buy	+190,000	New	+$10.5M	3.61%	4
2022 Q2	–	Sell	-70,000	Closed	-$2.42M	–	74
2022 Q1	$2.42M	Buy	+70,000	New	+$2.09M	0.39%	37
2021 Q4	–	Sell	-75,000	Closed	-$1.91M	–	82
2021 Q3	$1.91M	Buy	75,000 +55,000	+275%	+$1.62M	0.48%	42
2021 Q2	$700K	Hold	20,000	–	–	0.25%	60
2021 Q1	$815K	Sell	20,000 -30,000	-60%	-$1.38M	0.28%	51
2020 Q4	$2.17M	Buy	+50,000	New	+$2.47M	1.15%	27

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Affinity Asset Advisors's GBT Position: Q4 2022 in Review

Affinity Asset Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 190,000 shares — an estimated $12.9M sold.

Affinity Asset Advisors first reported a position in GBT in Q4 2020 and held it in 6 quarters. The position peaked at $12.9M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Affinity Asset Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Affinity Asset Advisors sold 190,000 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $12.9M.
Affinity Asset Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 6 quarters.
Affinity Asset Advisors's Global Blood Therapeutics, Inc. position peaked at $12.9M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.